Abstract Number: PB3180 About the study The triple combination arm in the ongoing Phase 2a study combines the subcutaneous formulation of BI-1206 and rituximab with Calquence ® (acalabrutinib) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback